196 related articles for article (PubMed ID: 27692193)
1. Non-Prescribed Buprenorphine in New York City: Motivations for Use, Practices of Diversion, and Experiences of Stigma.
Allen B; Harocopos A
J Subst Abuse Treat; 2016 Nov; 70():81-86. PubMed ID: 27692193
[TBL] [Abstract][Full Text] [Related]
2. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.
Johnson B; Richert T
Harm Reduct J; 2019 May; 16(1):31. PubMed ID: 31046774
[TBL] [Abstract][Full Text] [Related]
3. Circumstances and contexts of heroin initiation following non-medical opioid analgesic use in New York City.
Harocopos A; Allen B; Paone D
Int J Drug Policy; 2016 Feb; 28():106-12. PubMed ID: 26818082
[TBL] [Abstract][Full Text] [Related]
4. High enhancer, downer, withdrawal helper: Multifunctional nonmedical benzodiazepine use among young adult opioid users in New York City.
Mateu-Gelabert P; Jessell L; Goodbody E; Kim D; Gile K; Teubl J; Syckes C; Ruggles K; Lazar J; Friedman S; Guarino H
Int J Drug Policy; 2017 Aug; 46():17-27. PubMed ID: 28577506
[TBL] [Abstract][Full Text] [Related]
5. Understanding the use of diverted buprenorphine.
Cicero TJ; Ellis MS; Chilcoat HD
Drug Alcohol Depend; 2018 Dec; 193():117-123. PubMed ID: 30359928
[TBL] [Abstract][Full Text] [Related]
6. The More Things Change: Buprenorphine/naloxone Diversion Continues While Treatment Remains Inaccessible.
Carroll JJ; Rich JD; Green TC
J Addict Med; 2018; 12(6):459-465. PubMed ID: 30095563
[TBL] [Abstract][Full Text] [Related]
7. The relationship between diversion-related attitudes and sharing and selling buprenorphine.
Kenney SR; Anderson BJ; Bailey GL; Stein MD
J Subst Abuse Treat; 2017 Jul; 78():43-47. PubMed ID: 28554602
[TBL] [Abstract][Full Text] [Related]
8. Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?
Doernberg M; Krawczyk N; Agus D; Fingerhood M
Subst Abus; 2019; 40(2):148-153. PubMed ID: 31008694
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine in the United States: Motives for abuse, misuse, and diversion.
Chilcoat HD; Amick HR; Sherwood MR; Dunn KE
J Subst Abuse Treat; 2019 Sep; 104():148-157. PubMed ID: 31370979
[TBL] [Abstract][Full Text] [Related]
10. On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine.
Silverstein SM; Daniulaityte R; Miller SC; Martins SS; Carlson RG
Drug Alcohol Depend; 2020 May; 210():107958. PubMed ID: 32203863
[TBL] [Abstract][Full Text] [Related]
11. "I'm Not a Good Drug Dealer": Styles of Buprenorphine Diversion in a Multisite Qualitative Study.
McLean K; Kavanaugh PR
Subst Use Misuse; 2022; 57(3):452-460. PubMed ID: 35067160
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
[TBL] [Abstract][Full Text] [Related]
13. Buprenorphine prescribing practice trends and attitudes among New York providers.
Kermack A; Flannery M; Tofighi B; McNeely J; Lee JD
J Subst Abuse Treat; 2017 Mar; 74():1-6. PubMed ID: 28132694
[TBL] [Abstract][Full Text] [Related]
14. Diversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden: prevalence estimates and risk factors.
Johnson B; Richert T
Int J Drug Policy; 2015 Feb; 26(2):183-90. PubMed ID: 25465344
[TBL] [Abstract][Full Text] [Related]
15. Diffusion and diversion of suboxone: an exploration of illicit street opioid selling.
Furst RT
J Addict Dis; 2014; 33(3):177-86. PubMed ID: 25115236
[TBL] [Abstract][Full Text] [Related]
16. Exploring prison buprenorphine misuse in the United Kingdom: a qualitative study of former prisoners.
Tompkins CN; Wright NM; Waterman MG; Sheard L
Int J Prison Health; 2009; 5(2):71-87. PubMed ID: 25759139
[TBL] [Abstract][Full Text] [Related]
17. Assessing Motivations for Nonprescribed Buprenorphine Use Among Rural Appalachian Substance Users.
McDonald MJ; DeVeaugh-Geiss AM; Chilcoat HD; Havens JR
J Addict Med; 2023 Jan-Feb 01; 17(1):95-100. PubMed ID: 36044288
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.
Montesano F; Zaccone D; Battaglia E; Genco F; Mellace V
Clin Drug Investig; 2010; 30 Suppl 1():13-9. PubMed ID: 20450241
[TBL] [Abstract][Full Text] [Related]
19. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
Walsh SL; Nuzzo PA; Babalonis S; Casselton V; Lofwall MR
Drug Alcohol Depend; 2016 May; 162():190-8. PubMed ID: 27012435
[TBL] [Abstract][Full Text] [Related]
20. Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore City.
Truong C; Krawczyk N; Dejman M; Marshall-Shah S; Tormohlen K; Agus D; Bass J
Addict Behav; 2019 Jun; 93():14-19. PubMed ID: 30682677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
